Article Details
Retrieved on: 2024-04-17 22:08:06
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses how adjuvant therapy with pembrolizumab, an immunotherapy drug, improves overall survival in kidney cancer patients post-surgery, with research led by the Dana-Farber Cancer Institute and published in the NEJM.
Article found on: www.eurekalert.org
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here